Item 8.01. Other Events.

On September 26 2022, the Company issued a press release announcing positive final results from its Phase 2 trial of vurolenatide in short bowel syndrome and successful end-of-Phase 2 meeting with the U.S. Food and Drug Administration. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On September 26, 2022, the Company provided an overview of vurolenatide for short bowel syndrome which can be found on the Company's website at www.9meters.com under the section titled Investors. A copy of the Company's presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.




Item 9.01.     Financial Statements and Exhibits.



(d) Exhibits

Exhibit No.           Description
Exhibit 99.1            Press Release dated September 26, 2022.
Exhibit 99.2            9 Meters Biopharma, Inc. Corporate Presentation.
Exhibit 104           Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses